VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

NextCure, Inc. (NXTC) Total Return Calculator with Dividends Reinvested

NextCure, Inc.

Popular:

The total return for NextCure, Inc. (NXTC) stock is +123.25% over the past 12 months. So far it's down 23.34% this year. The 5-year total return is -89.33%, meaning $10,000 invested in NXTC stock 5 years ago would be worth $1,067 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in NXTC 1 year ago, it would be worth $22,035 today — you'd have gained $12,035.

With Dividends Reinvested$22,035+120.35%

Price Only (No DRIP)$22,035+120.35%

Period2025-05-08 → 2026-05-07

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in NXTC

1Y$22,325+$12,325 (+123.2%)123.2% CAGR

3Y$5,237-$4,763 (-47.6%)-19.4% CAGR

5Y$1,067-$8,933 (-89.3%)-36.1% CAGR

10Y$426-$9,574 (-95.7%)-27.1% CAGR

15Y$426-$9,574 (-95.7%)-19.0% CAGR

20Y$426-$9,574 (-95.7%)-14.6% CAGR

30Y$426-$9,574 (-95.7%)-10.0% CAGR

NextCure, Inc. did not pay dividends during this period. Total return = price return.

Loading NXTC total return...

As of 2026-05-08

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-23.34%	—	-23.34%	—	$7,666
1Y	+123.25%	123.25%	+123.25%	—	$22,325
3Y	-47.63%	-19.40%	-47.63%	—	$5,237
5Y	-89.33%	-36.08%	-89.33%	—	$1,067
10Y	-95.74%	-27.06%	-95.74%	—	$426
15Y	-95.74%	-18.97%	-95.74%	—	$426
20Y	-95.74%	-14.59%	-95.74%	—	$426
30Y	-95.74%	-9.98%	-95.74%	—	$426

Risk & Highlights

Best Year+183.07%2019

Worst Year-80.42%2020

Max Drawdown-41.98%2025-06-13 → 2025-07-11 · Recovered 2025-10-16

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-4.22%	-4.22%	—	+0.41%	-4.6pp
2025	+43.91%	+43.91%	—	+16.64%	+27.3pp
2024	-32.97%	-32.97%	—	+24.00%	-57.0pp
2023	-23.49%	-23.49%	—	+24.81%	-48.3pp
2022	-77.40%	-77.40%	—	-19.95%	-57.5pp

NXTC outperformed the S&P 500 by 92.87pp over the past year (+123.25% vs +30.37%).

Loading summary...

NXTC Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
NXTCNextCure, Inc.	$27M	-10.2%	-23.3%	+123.2%	—	-47.6%	-89.3%	-95.7%
FATEFate Therapeutics, Inc.	$280M	+111.3%	+145.5%	+143.0%	—	-55.4%	-96.8%	+40.5%
RCUSArcus Biosciences, Inc.	$2.5B	+12.3%	+6.5%	+209.6%	—	+24.9%	-18.6%	+45.9%
AGENAgenus Inc.	$132M	-7.6%	+16.1%	+27.1%	—	-88.2%	-93.9%	-94.3%
IMVTImmunovant, Inc.	$5.5B	+10.6%	+5.1%	+96.1%	—	+40.9%	+62.4%	+173.6%
TGTXTG Therapeutics, Inc.	$6.9B	+28.9%	+46.9%	+23.5%	—	+30.0%	+7.0%	+436.5%
KYMRKymera Therapeutics, Inc.	$6.9B	-0.6%	+16.3%	+190.7%	—	+205.1%	+92.1%	+154.4%
INCYIncyte Corporation	$19.5B	+4.4%	-3.6%	+64.2%	—	+48.6%	+18.2%	+34.2%
EXELExelixis, Inc.	$11.7B	+5.0%	+6.0%	+25.5%	—	+142.8%	+84.0%	+833.5%
MGNXMacroGenics, Inc.	$186M	-12.2%	+82.6%	+97.3%	—	-59.4%	-90.8%	-84.4%
ALKSAlkermes plc	$5.9B	+7.2%	+25.3%	+16.5%	—	+14.5%	+60.9%	-11.0%

Compare:NXTC vs FATE NXTC vs RCUS NXTC vs AGEN NXTC vs FATE vs RCUS

About NXTC Dividend Returns

NextCure, Inc. (NXTC) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of NXTC over the past year?

NextCure, Inc. (NXTC) delivered a return of 123.25% over the past year. Since NXTC does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in NXTC be worth today?

A $10,000 investment in NextCure, Inc. one year ago would be worth $22,325 today, representing a gain of $12,325.

Q3Does NXTC pay dividends?

NextCure, Inc. (NXTC) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For NXTC, the total return equals the price-only return.

Q4Did NXTC beat the S&P 500?

Yes, NextCure, Inc. (NXTC) outperformed the S&P 500 by 92.87 percentage points over the past year. NXTC delivered a total return of 123.25%, compared to the S&P 500's 30.37%. This 92.87pp alpha means investors in NXTC earned more than a passive S&P 500 index fund.

Q5What is NXTC's worst drawdown?

NextCure, Inc. (NXTC) experienced a maximum drawdown of -41.98% over the past year, declining from its peak on 2025-06-13 to its trough on 2025-07-11. The stock recovered to its prior peak by 2025-10-16. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is NXTC's long-term total return over 10, 20, or 30 years?

Here are NextCure, Inc. (NXTC)'s long-term returns with dividends reinvested. Over 10 years, the total return is -95.7% (-27.1% CAGR) — $10,000 would have grown to $426. Over 20 years: -95.7% total return (-14.6% CAGR) — $10,000 → $426. Over 30 years: -95.7% total return (-10.0% CAGR) — $10,000 → $426. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was NXTC's best and worst year?

NextCure, Inc.'s best calendar year was 2019 with a total return of 183.1%. Its worst year was 2020 with a total return of -80.4%. This range shows the volatility investors should expect — the difference between the best and worst year is 263.5 percentage points.